Digital Health Just Raised $7.4 Billion. Addiction Treatment Barely Shows Up in the Count.

Rock Health’s mid-year tally landed this week with a headline number that sounds like good news for digital health broadly: $7.4 billion raised across 244 deals in the first half of 2026, up from $6.4 billion a year earlier. Mental health held its title as the single most-funded clinical category for a seventh consecutive year, led by mega-rounds like Talkiatry’s $210 million Series D and Grow Therapy’s $150 million raise.

Money is flooding into digital behavioral health right now, and almost none of the biggest checks are being written for people whose primary diagnosis is a substance use disorder.

The concentration is the real story here, not the total. Mega-deals of $100 million or more absorbed 45% of all capital raised in H1 2026, up from just 22% in 2024, according to Healthcare Dive’s read of the same data. That’s a market where investors are making fewer, larger bets on companies that already have traction — which is exactly the dynamic that squeezes out addiction-focused startups mid-raise, since SUD companies have historically needed more time to prove outcomes before they look like a mega-round candidate. Several virtual addiction-treatment providers have raised real money in past funding cycles, but none show up among this half’s marquee deals, and the public reporting on this report doesn’t break out addiction treatment as its own line item at all — it gets folded into “mental health,” which is generous packaging for a category that competes for the same dollar as therapy apps and psychiatry platforms with faster, cleaner revenue stories.

For a field that treats 48.5 million Americans with a substance use disorder while only reaching about 15% of them, disappearing into someone else’s category on a funding scoreboard is its own kind of signal. The money hasn’t stopped moving. It’s just moving toward the pitch that’s easiest to explain to a board in one slide — and addiction treatment, with its slower outcomes timeline and its patients who don’t always fit neatly into a subscription-retention chart, is still the harder slide to make.